Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil

Core Insights - Beyond Air, Inc. has expanded its international distribution network for LungFit PH to 39 countries, covering a population of over three billion people [1][2] - The company aims to leverage its unique nitric oxide delivery technology to gain significant market share in key international markets [2] - LungFit PH is designed to generate nitric oxide from ambient air, streamlining hospital operations and reducing environmental impact [3][6] Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on using nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors [4] - The company has received FDA approval and CE Mark for LungFit PH, which is intended for treating neonates with hypoxic respiratory failure [4][8] - Beyond Air is advancing other LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia and nontuberculous mycobacteria [4] Product Details - LungFit PH is a cylinder-free, phasic flow generator that can deliver nitric oxide at concentrations ranging from 1 ppm to 80 ppm [6] - The device is compatible with ventilators and aims to replace traditional high-pressure nitric oxide cylinders, offering operational benefits such as reduced inventory and improved safety [6][7] - Beyond Air plans to extend the use of LungFit technology for home treatment of chronic lung infections [7] Research and Development - The company has partnered with The Hebrew University of Jerusalem to develop treatments for autism spectrum disorder and other neurological conditions [5] - Beyond Cancer, Ltd., an affiliate of Beyond Air, is exploring high concentrations of nitric oxide for targeting solid tumors in pre-clinical studies [5]